Parenteral lipid emulsion induces germination of Candida albicans and increases biofilm formation on medical catheter surfaces

Journal of Infectious Diseases

Volumn 200, Issue 3, 2009, Pages 473-480

  Swindell, Kim ^a,b   Lattif, Ali Abdul ^a,b   Chandra, Jyotsna ^a,b   Mukherjee, Pranab K ^a,b   Ghannoum, Mahmoud A ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERGOCALCIFEROL; LIPID EMULSION; SILASTIC;

ARTICLE; BIOFILM; CANDIDA ALBICANS; CATHETER; COLONY FORMING UNIT; CONTROLLED STUDY; DRY WEIGHT; FUNGAL MORPHOLOGY; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS GROWTH; GERMINATION; NONHUMAN; PRIORITY JOURNAL;

BIOFILMS; CANDIDA ALBICANS; CATHETERIZATION; EQUIPMENT CONTAMINATION; FAT EMULSIONS, INTRAVENOUS; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING; SURFACE PROPERTIES;

EID: 67650660996     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/600106     Document Type: Article

References (47)

1. Hawser SP, Douglas LJ. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect Immun 1994;62:915-21.
2. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev 2004; 17:255-67.
3. Wisplinghoff H, Bischoff K, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17.
4. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004;42:1519-27.
5. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 2001; 183: 5385-94.
6. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol 2003; 11:30-6.
7. Jin Y, Yip HK, Samaranayake YH, Yau JY, Samaranayake LP. Biofilmforming ability of Candida albicans is unlikely to contribute to high levels of oral yeast carriage in cases of human immunodeficiency virus infection. J Clin Microbiol 2003;41:2961-7.
8. Li X, Yan Z, Xu J. Quantitative variation of biofilms among strains in natural populations of Candida albicans. Microbiology 2003; 149: 353-62.
9. Shin JH, Kee SJ, Shin MG, et al. Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 2002;40:1244-8.
10. Hawser SP, Douglas LJ. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect Immun 1994;62:915-21.
11. Ramage G, Bachmann S, Patterson TF, Wickes BL, Lopez-Ribot JL. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 2002; 49:973-80.
12. Kuhn DM, Mukherjee PK, Clark TA, et al. Candida parapsilosis characterization in an outbreak setting. Emerg Infect Dis 2004; 10:1074-81.
13. Ruzicka F, Hola V, Votova M, Tejkalova RF. Detection and significance of biofilm formation in yeast isolated from hemocultures [in Czech]. Klin Mikrobiol lnfekc Lek 2006; 12:150-5.
14. Tumbarello M, Posteraro B, Trecarichi EM, et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol 2007; 45: 1843-50.
15. Hawser SP, Douglas LJ. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 1995; 39: 2128-31.
16. Kuhn DM, Ghannoum MA. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs 2004; 5: 186-97.
17. Kumamoto CA. Candida biofilms. Curr Opin Microbiol 2002; 5:608-11.
18. Pappas PG, Rex JH, Rex JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-89.
19. Wilmer A, Van den Berghe G. Parenteral nutrition. In: L. Goldman, D. Ausiello, eds. Cecil medicine. Philadelphia: Saunders Elsevier, 2008: 1621-6.
20. Almirante B, Rodríguez D, Cuenca-Estrella M, et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006;44:1681-5.
21. Amrutkar PP, Rege MD, Chen H, LaRocco MT, Gentry LO, Garey KW. Comparison of risk factors for candidemia versus bacteremia in hospitalized patients. Infection 2006; 34:322-7.
22. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMlS prospective multicenter study. National Epidemiology of Mycoses Survey (NEMlS) Study Group. Clin Infect Dis 2001;33:177-86.
23. Chakrabarti C, Sood SK, Parnell V, Rubin LG. Prolonged candidemia in infants following surgery for congenital heart disease. Infect Control Hosp Epidemiol 2003; 24:753-7.
24. Pearlman SE, Saiman L, Larson EL. Risk factors for late-onset health care-associated bloodstream infections in patients in neonatal intensive care units. Am J Infect Control 2007;35:177-82.
25. Weese-Mayer DE, Fondriest DW, Brouillette RT, Shulman ST. Risk factors associated with candidemia in the neonatal intensive care unit: a case-control study. Pediatr Infect Dis J 1987;6:190-6.
26. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Pediatrics 2002; 110:e51.
27. Crocker KS, Noga R, Filibeck DJ, Krey SH, Markovic M, Steffee WP. Microbial growth comparisons of five commercial parenteral lipid emulsions. JPEN J Parenter Enteral Nutr 1984; 8:391-5.
28. D'Angio R, Quercia RA, Treiber NK, Mclaughlin JC, Klimek J. The growth of microorganisms in total parenteral admixtures. JPEN J Parenter Enteral Nutr 1987; 11:394-7.
29. Deitei M, Kaminsky VM, Fuksa M. Growth of common bacteria and Candida albicans in 10% soybean oil emulsion. Can J Surg 1975; 18: 531-5.
30. Didier ME, Fischer S, Maki DG. Total nutrient admixtures appear safer than lipid emulsion alone as regards microbial contamination: growth properties of microbial pathogens at room temperature. JPEN J Parenter Enteral Nutr 1998;22:291-6.
31. Gilbert M, Gallagher SC, Eads M, Elmore MF. Microbial growth patterns in a parenteral formulation containing lipid emulsion. JPEN J Parenter Enteral Nutr 1986; 10:494-7.
32. Lawrence J, Turner M, Gilbert P. Microbial contamination in total parenteral nutrition solutions. J Clin Pharm Ther 1988; 13:151-7.
33. Maki DG, Martin WT. Nationwide epidemic of septicemia caused by contaminated infusion products. IV. Growth of microbial pathogens in fluids for intravenous infusions. J Infect Dis 1975; 131:267-72.
34. Melly MA, Meng HC, Schaffner W. Microbiol growth in lipid emulsions used in parenteral nutrition. Arch Surg 1975; 110:1479-81.
35. Mershon J, Nogami W, Williams JM, Yoder C, Eitzen HE, Lemons JA. Bacterial/fungal growth in a combined parenteral nutrition solution. JPEN J Parenter Enteral Nutr 1986; 10:498-502.
36. Tessler M, Dascal A, Gioseffini S, Miller M, Mendelson J. Growth curves of Staphylococcus aureus, Candida albicans, and Moraxella osloensis in propofol and other media. Can J Anaesth 1992;39:509-11.
37. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 2002; 70:878-88.
38. Gillum AM, Tsay EYH, Kirsch DR. Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 1984; 198:179-82.
39. Chandra J, Mukherjee PK, Leidich SD, et al. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res 2001; 80:903-8.
40. Keammerer D, Mayhall CG, Hall GO, Pesko LJ, Thomas RB. Microbial growth patterns in intravenous fat emulsions. Am J Hosp Pharm 1983; 40:1650-3.
41. Stoodley P, Sauer K, Davies DG, Costerton JW. Biofilms as complex differentiated communities. Annu Rev Microbiol 2002;56:187-209.
42. Nobile, CJ, Andes DR, Nett JE, et al. Critical role of Bcrl-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS Pathog 2006; 2:e63.
43. Phan QT, Myers CL, Fu Y, et al. Als3 is a Candida albicans invasin that binds to Cadherins and induces endocytosis by host cells. PLoS Biol 2007; 5:e64.
44. Staab JF, Bradway SD, Fidel PL, Sundstrom P. Adhesive and mammalian transglutaminase substrate properties of Candida albicans Hwpl. Science 1999;283:1535-8.
45. Hoberg KA, Cihlar RL, Calderone RA. Inhibitory effect of cerulenin and sodium butyrate on germination of Candida albicans. Antimicrob Agents Chemother 1983;24:401-8.
46. Noverr MC, Huffhagle GB. Regulation of Candida albicans morphogenesis by fatty acid metabolites. Infect Immun 2004; 72:6206-10.
47. Andes D, Nett J, Oschel P, Albrecht R, Marchillo K, Pitula A. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun 2004;72:6023-31.